Ignite Creation Date:
2024-05-06 @ 10:18 AM
Last Modification Date:
2024-10-26 @ 12:27 PM
Study NCT ID:
NCT03214250
Status:
COMPLETED
Last Update Posted:
2022-12-23
First Post:
2017-06-09
Brief Title:
Safety and Efficacy of APX005M With Gemcitabine and Nab-Paclitaxel With or Without Nivolumab in Patients With Previously Untreated Metastatic Pancreatic Adenocarcinoma
Sponsor:
Parker Institute for Cancer Immunotherapy
Organization:
Parker Institute for Cancer Immunotherapy
Study Overview
Official Title:
Open-label Multicenter Phase 1b2 Clinical Study to Evaluate the Safety and Efficacy of CD40 Agonistic Monoclonal Antibody APX005M Administered Together With Gemcitabine and Nab-Paclitaxel With or Without PD-1 Blocking Antibody Nivolumab in Patients With Previously Untreated Metastatic Pancreatic Adenocarcinoma
Status:
COMPLETED
Status Verified Date:
2022-12
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The main purposes of this study are to learn how effective the study drug combinations are in treating patients with metastatic pancreatic adenocarcinoma The drug combinations are APX005MNivolumabGemcitabinenab-Paclitaxel or APX005MGemcitabinenab-Paclitaxel
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
True
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| UPCC 11217 | OTHER | University of Pennsylvania | None |